DSGN
Design Therapeutics, Inc.NASDAQHealthcare$11.23+2.00%ClosedMarket Cap: $692.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
3.38
P/S
0.00
EV/EBITDA
-10.22
DCF Value
$0.27
FCF Yield
-7.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.7%
ROA
-30.9%
ROIC
-37.3%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | Infinity% | $-18.2M | $-16.0M | $-0.27 | — |
| FY 2025 | $0.00 | -Infinity% | $-79.5M | $-69.8M | $-1.22 | — |
| Q3 2025 | $0.00 | -Infinity% | $-19.3M | $-17.0M | $-0.30 | — |
| Q2 2025 | $0.00 | -Infinity% | $-21.6M | $-19.1M | $-0.34 | — |
| Q1 2025 | $0.00 | NaN% | $-20.4M | $-17.7M | $-0.31 | — |
| Q4 2024 | $0.00 | NaN% | $-16.7M | $-13.7M | $-0.24 | — |
| FY 2024 | $0.00 | -Infinity% | $-62.4M | $-49.6M | $-0.88 | — |
| Q3 2024 | $0.00 | NaN% | $-16.2M | $-13.0M | $-0.23 | — |
| Q2 2024 | $0.00 | -Infinity% | $-15.0M | $-11.8M | $-0.21 | — |
| Q1 2024 | $0.00 | -Infinity% | $-14.4M | $-11.1M | $-0.20 | — |
| Q4 2023 | $0.00 | NaN% | $-15.1M | $-11.8M | $-0.21 | — |
| FY 2023 | $0.00 | -Infinity% | $-78.2M | $-66.9M | $-1.19 | — |